---
title: "Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Expanded access program"
description: "Formulary evidence on Adrabetadex (Lembaz, VTS-270) in Infantile-onset Niemann-Pick disease type C: Expanded access program. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 62 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence/expanded-access-program"
published: "2026-11-19T12:08:36-05:00"
modified: "2026-11-19T12:08:36-05:00"
---

# Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Expanded access program

<a id="heading-3.1.5"></a>

## 3.1.5 Expanded Access Program

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Purpose of the original Rush expanded access protocol

> “The protocol was developed to allow access to treatment for 001-01, who was showing relatively rapid disease progression and could not enroll in the phase 1/2a trial.”
> “In this study, the long-term effects of intrathecal HPβCD treatment for 2.5–3 years in humans with NPC were evaluated.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.1-2"></a>

#### Objective of the survival analysis by baseline disease burden

> “To evaluate overall survival among individuals with I-NPC treated with adrabetadex and an untreated cohort, stratified by baseline disease burden.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.1-3"></a>

#### Objective of the prompt versus delayed treatment analysis

> “This analysis evaluates outcomes in participants with I-NPC receiving prompt versus delayed adrabetadex treatment following diagnosis.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.1-4"></a>

#### Objective of the combination therapy analysis

> “To describe baseline characteristics, treatment sequencing, safety outcomes, and combination therapy patterns in a cohort of participants treated with adrabetadex plus arimoclomol and/or levacetylleucine in an adrabetadex expanded access program (EAP), and to evaluate evidence of an emerging combination treatment paradigm in NPC.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Expanded access protocol under IND 119856 at Rush University Medical Center, with drug provided by Mandos Health

> “Intrathecal adrabetadex was administered under an expanded access protocol (IND 119856) and reliance agreement with NIH approved by the Rush University Medical Center IRB.”
> “EBK has received funds to consult and/or run clinical trials for commercial programs focused in NPC including Orphazyme, Zevra, Intrabio, Vtesse, Sucampo, Mallinckrodt, and runs an expanded access program for adrabetadex for which drug is provided by Mandos Health.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="topic-3.1.5.2-2"></a>

#### Program start in 2013

> “Individuals with I-NPC were eligible to participate in an intrathecal adrabetadex expanded access program (EAP) that was initiated in 2013.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.2-3"></a>

#### Institutional review board approval of the original protocol

> “The Rush University Medical Center IRB approved the protocol, and legal guardians of all subjects signed informed consent.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.2-4"></a>

#### Evaluation sites for expanded access participants in a biomarker study

> “For the EAP participants in this analysis, evaluations were conducted at RUSH University Medical Center, Yale University, or University of California Los Angeles (UCLA).”

Source: [Padilla et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970998/)

<a id="topic-3.1.5.2-5"></a>

#### Active and pending sites, December 2021

> “14 distinct sites are currently active in EAP”
> “5 pending new sites for EAP”

Source: [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)

<a id="topic-3.1.5.2-6"></a>

#### Agreement with the FDA to continue the program beyond October 2021

> “We are thrilled today to announce that we’ve reached agreement with the FDA to officially continue the US Expanded Access Program (EAP) for intrathecal administration of adrabetadex”
> “beyond October 20th, 2021.”

Source: [Mandos expanded access program continuation letter (2021)](https://www.berentx.com/news/npc-expanded-access-program-continues-september-2021/)

<a id="topic-3.1.5.2-7"></a>

#### Data cutoff of the combination therapy analysis

> “Data analysis cut-off date is March 27, 2026.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Label description of the expanded access program data

> “The expanded access program data included 85 patients with neurological manifestations of NPC between 1 and 43 years of age (mean age was 12 years) who were treatment-naïve (71 patients) or previously treated (14 patients) under Trials 1, 2, and 3.”
> “The duration of the expanded access program was open-ended; mean (SD) duration of treatment with LEMBAZ was 44 (32) months.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.5.3-2"></a>

#### Intermediate-size patient population IND modeled on the phase 1/2a trial

> “In order to treat her brother, 001-02, at the same time, the expanded access application was submitted to FDA as an intermediate-size patient population IND (IND 119856).”
> “The protocol was designed to parallel the ongoing phase 1/2a trial, with 2-week dosing intervals as opposed to the 4-week intervals in the phase 1/2a trial.”
> “We report here results from three patients treated with IT HPβCD via expanded access through an intermediate-size patient population IND.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.3-3"></a>

#### Safety data collection in the combination therapy analysis

> “Safety data were not available for patients receiving other NPC therapies prior to study enrollment.”
> “Safety data were only collected while participants were in the study and receiving adrabetadex.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.3-4"></a>

#### Prompt versus delayed treatment analysis of participants treated for at least 5 years

> “The EAP population was surveyed for participants with disease onset <6 years of age and who had sustained treatment for ≥5 years.”
> “Change from baseline in R4DNPCCSS score was summarized for participants treated with adrabetadex within <1 year (prompt treatment) versus ≥1 year (delayed treatment) from neurological onset.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.3-5"></a>

#### Survival analysis of pooled clinical study and expanded access participants by baseline disease burden

> “This analysis evaluated overall survival in adrabetadex-treated participants with I-NPC stratified by baseline disease burden using a rescored 4-domain NPC Clinical Severity Scale (R4DNPCCSS).”
> “Overall survival was estimated using the Kaplan–Meier (KM) method for the adrabetadex-treated participants and for an untreated cohort from the National Institutes of Health (NIH) natural history study of NPC.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.3-6"></a>

#### Sibling case report design

> “Disease progression before and after adrabetadex initiation was monitored using the Rescored 4-domain Niemann-Pick disease type C Clinical Severity Scale (R4DNPCCSS), a disease-specific clinical severity scale which assesses ambulation, fine motor skills, speech, and rescored swallowing.”
> “Qualitative physician assessments were performed at each visit.”

Source: [Julich et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Julich_2026_CNS-Poster_Sibling-Case-Study_09Oct2026_Final-1.pdf)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Ineligibility for enrolling clinical trials

> “Enrollment in the EAP was initiated in 2013 and required that participants be ineligible for all currently enrolling clinical trials.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.4-2"></a>

#### Access for patients unable to enroll in trials

> “These protocols included a natural history/observational study (NCT00344331), phase I/II and phase II/III studies of intrathecal VTS‐270/adrabetadex (NCT01747135 and NCT02534844), and an expanded access program for access to intrathecal VTS‐270/adrabetadex for patients with NPC1 who were unable to enroll in trials (IND 119856).”

Source: [Cawley et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11893204/)

<a id="topic-3.1.5.4-3"></a>

#### Trial ineligibility of the first three expanded access patients

> “At age 13 she screened for the phase 1/2a trial of IT HPβCD but was ineligible due to multiple anticonvulsants and vagal nerve stimulator use.”
> “He was not able to enter the phase 1/2a trial.”
> “001-03 could not enter the phase 1/2a trial of HPβCD as it was closed when the family requested screening.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.4-4"></a>

#### Continued-benefit criteria for participants leaving the VTS301 trial, December 2021

> “We were thrilled to be able to support the patients who wanted to continue with their adrabetadex treatments following the conclusion of their clinical trial participation.”
> “We are most appreciative for the preparation and vigilance from everyone involved with the Expanded Access Program (EAP) who enabled those patients who met the eligibility criteria for continued benefit to enroll into the expanded access program and continue treatment without interruption.”

Source: [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)

<a id="topic-3.1.5.4-5"></a>

#### Supply per FDA risk-benefit criteria, November 2022

> “We want to reinforce that we will continue to provide adrabetadex for the North American Expanded Access Program (EAP) per the criteria regarding risk/benefit from FDA.”

Source: [Mandos November 2022 community update (2022)](https://www.berentx.com/news/npc-community-update-november-2022/)

<a id="topic-3.1.5.4-6"></a>

#### Age criteria expanded to 3 months to 25 years, September 2024

> “Recently, after discussions with the FDA, the EAP age criteria have been expanded to include patients from 3 months to 25 years old.”

Source: [Beren Therapeutics September 2024 community update (2024)](https://www.berentx.com/news/npc-community-update-september-2024/)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Label dosing in the expanded access program

> “Treatment-naïve patients were dosed intrathecally every two weeks at a starting intrathecal LEMBAZ dosage of 200 mg (less than 4 years of age) or 400 mg (4 years of age or older).”
> “The LEMBAZ dosage was increased to a maximum of 600 mg (for patients who weighed 7 to 12 kg) or 900 mg (for patients who weighed more than 12 kg) every two weeks.”
> “Patients already receiving LEMBAZ continued at their current stable dosage.”

Source: [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf)

<a id="topic-3.1.5.5-2"></a>

#### Titration ceilings of the initial and revised expanded access protocols

> “In the EAP, the adrabetadex dose started at 200 mg or 400 mg based on age every 2 weeks with stepwise titration up to 1200 mg in the initial protocol or 900 mg in the later revision, and dose adjustments were allowed.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.5-3"></a>

#### Formulation, route, and dose range of the original Rush protocol

> “A formulation of HPβCD with a specific chemical fingerprint was obtained from Janssen Research & Development, LLC initially and then Vtesse, Inc. (VTS-270, same formulation) and in all cases was administered by intrathecal infusion via lumbar puncture every two weeks.”
> “The initial protocol was written to dose escalate from 200 mg to 400 mg (accepted dose range at the time) over 4 months based on safety.”
> “The protocol was amended to allow dosing based on tolerability within a range from 200 mg-1200 mg.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.5-4"></a>

#### Doses and dosing intervals in a long-term treated cohort

> “Intrathecal doses of adrabetadex at the time of sample collection ranged from 300–900 mg (mean 660 ± 216 mg).”
> “Interval between doses was either 2 weeks (n=6) or 4 weeks (n=4).”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="topic-3.1.5.5-5"></a>

#### Doses in the sibling case report

> “She subsequently enrolled in an Expanded Access Program (EAP) and continued to receive adrabetadex.”
> “Sibling A currently receives adrabetadex 500 mg Q2W in the EAP.”
> “Sibling B initiated intrathecal adrabetadex in the EAP approximately 10 months after neurological symptom onset, at an initial dose of 200 mg Q2W.”
> “Sibling B currently receives adrabetadex 500 mg Q2W in the EAP.”

Source: [Julich et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Julich_2026_CNS-Poster_Sibling-Case-Study_09Oct2026_Final-1.pdf)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Rescored 4-domain NPC Clinical Severity Scale as the Disease Progression Outcome

<a id="topic-3.1.5.6.1-1"></a>

##### Domains of the rescored 4-domain scale and burden quartiles

> “The R4DNPCCSS is a modified version of the 5-domain NPCCSS, which includes the domains most relevant to patients, caregivers, and clinicians: ambulation, swallowing, cognition, speech, and fine-motor.”
> “The R4DNPCCSS eliminates the cognitive domain and adds an improved swallow scoring algorithm.”
> “Baseline R4DNPCCSS scores (0–20 composite score; higher scores indicate greater impairment) were used to stratify participants into disease burden groups defined by quartiles (minimal [≤4], mild [5 to 8], moderate [9 to 12], severe [≥13]).”
> “This analysis was updated from tertiles to quartiles to better reflect NPC disease characteristics.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.6.1-2"></a>

##### Hearing items excluded from severity scores because of cyclodextrin ototoxicity

> “Hearing items were scored at baseline to evaluate disease severity, but efficacy assessment scores excluded hearing and auditory brainstem response items, as hearing loss is a known side effect of HPβCD.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

> “The hearing domain was removed due to the known ototoxicity of 2HPβCD.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Participants enrolled, December 2021

| Field | Dashboard |
| --- | --- |
| Current patients enrolled in Expanded Access Program | “50 patients” |

Source: [Mandos December 2021 community update (2021)](https://www.berentx.com/news/npc-community-update-december-2021/)

<a id="topic-3.1.5.7.1-2"></a>

##### Participants enrolled, February 2026

> “We remain committed to providing adrabetadex to the more than 60 patients currently enrolled in the EAP, and to supporting continuity of care should adrabetadex receive regulatory approval.”

Source: [Beren Therapeutics webinar community update (2026)](https://www.berentx.com/news/npc-webinar-highlights-path-forward-february-2026/)

<a id="topic-3.1.5.7.1-3"></a>

##### Participants in the survival analysis by baseline disease burden

> “Summaries were carried out for adrabetadex-treated participants with I-NPC (neurological onset <6 years) in clinical studies or the Expanded Access Program (N=80; Supplementary Table 1) and for the untreated cohort (N=44; Supplementary Table 2).”
> “Seventy-six treated participants were included in the analysis stratified by minimal (n=29, 38.2%), mild (n=20, 26.3%), moderate (n=16, 21.1%), and severe (n=11, 14.5%) baseline R4DNPCCSS scores.”
> “A total of 4 participants did not have a baseline R4DNPCCSS score and were excluded from the analysis.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.7.1-4"></a>

##### Participants in the long-term 24(S)-hydroxycholesterol study

> “Ten individuals with NPC1 participated in this study.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Baseline definitions and survival comparisons in the disease burden analysis

> “Baseline was defined as the last available observation before the first adrabetadex dose date for the pooled adrabetadex-treated participants and the first available observation for participants in the untreated cohort.”
> “Within each cohort, estimates of survival across quartiles at baseline were compared using a Mantel–Haenszel log-rank test for trend.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.7.2-2"></a>

##### Combination therapy analysis groups and observation time

| Group (participants) | Definition |
| --- | --- |
| Adrabetadex first (28) | “Participants who started adrabetadex prior to adding levacetylleucine and/or arimoclomol” |
| Any combination exposure (33) | “Participants who had exposure to levacetylleucine and/or arimoclomol at any point” |
| No combination after adrabetadex (53) | “Participants with no record of starting arimoclomol and/or levacetylleucine after starting adrabetadex” |

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

> “Time since first treatment dose is time from the first dose of adrabetadex administration to date of discontinuation from EAP or EAP cutoff date, whichever occurred earlier.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.7.2-3"></a>

##### Statistical tests in the long-term 24(S)-hydroxycholesterol study

> “A paired t-test was used to evaluate the pre/post dosing 24(S) response and Mann-Whitney test was used to compare the nonresponding and responding groups.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Duration of treatment and follow-up in the 2026 analyses

> “Participants received adrabetadex treatment for up to 11.325 years.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

> “Duration of treatment ranged from approximately 5.3 to 8.7 years and 5.3 to 11.1 years for the prompt and delayed treatment groups, respectively.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.8.1-2"></a>

##### Time on treatment in the long-term 24(S)-hydroxycholesterol cohort

> “Average time since initiation of intrathecal adrabetadex was 7.2 ± 1.5 years with a range of 4.3 to 8.9 years.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="topic-3.1.5.8.1-3"></a>

##### Time since first dose and discontinuations in the expanded access program

| Measure | All EAP (n=86) |
| --- | --- |
| Time since first treatment dose, median [IQR], months | “52.8 [15.4, 74.2]” |
| TEAE leading to discontinuation, n (%) | “3 (3.5)” |
| TEAE leading to death, n (%) | “6 (7.0)” |

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Baseline characteristics of all expanded access participants

| Characteristic | All EAP (N=86) |
| --- | --- |
| Neurological onset <2 years, n (%) | “26 (30.2)” |
| Neurological onset 2 to 6 years, n (%) | “23 (26.7)” |
| Neurological onset ≥6 years, n (%) | “29 (33.7)” |
| Age at onset missing, n (%) | “8 (9.3)” |
| Age at neurological symptom onset, median (Q1, Q3), years (n=78) | “3.5 (1.5, 7.0)” |
| Age at adrabetadex treatment start, median (Q1, Q3), years (n=78) | “8.0 (3.0, 20.0)” |
| Male, n (%) | “51 (59.3)” |
| Female, n (%) | “34 (39.5)” |
| White, n (%) | “76 (88.4)” |
| Miglustat use at baseline, yes, n (%) | “33 (38.4)” |
| Miglustat use at baseline, no, n (%) | “46 (53.5)” |

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.8.2-2"></a>

##### Baseline characteristics of treated participants with infantile onset in the disease burden analysis

| Characteristic | Overall (N=76) |
| --- | --- |
| Neurological onset <2 years, n (%) | “33 (43.4)” |
| Neurological onset 2 to <6 years, n (%) | “43 (56.6)” |
| Age at neurological symptom onset, mean (SD), years | “2.5 (1.56)” |
| Age at adrabetadex treatment start, mean (SD), years | “7.7 (5.56)” |
| Age at adrabetadex treatment start, median (Q1, Q3), years | “6.2 (3.2, 10.8)” |
| Male, n (%) | “41 (53.9)” |
| White, n (%) | “66 (86.8)” |
| Baseline R4DNPCCSS, mean (SD) | “7.2 (5.06)” |
| Baseline R4DNPCCSS, median (Q1, Q3) | “7.0 (3.0, 10.0)” |

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.8.2-3"></a>

##### Baseline characteristics by time from onset to treatment

| Characteristic | Treatment initiation <1 year from onset (n=9) | Treatment initiation ≥1 year from onset (n=16) |
| --- | --- | --- |
| Age at neurological symptom onset, mean (SD), years | “2.11 (1.563)” | “2.65 (1.494)” |
| Age at adrabetadex treatment start, mean (SD), years | “2.70 (1.614)” | “7.15 (3.838)” |
| Duration from onset to treatment, mean (SD), years | “0.59 (0.324)” | “4.50 (3.308)” |
| Miglustat use at baseline, yes, n (%) | “1 (11.1)” | “9 (56.3)” |
| Baseline R4DNPCCSS, median (Q1, Q3) | “1.50 (0.50, 2.50)” | “5.00 (2.00, 10.00)” |
| Duration of treatment exposure, mean (SD), weeks | “348.37 (54.297)” | “397.23 (93.427)” |

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.8.2-4"></a>

##### Characteristics of the long-term 24(S)-hydroxycholesterol cohort

> “This cohort included 7 males and 3 females.”
> “Mean and median age were 20.1 ± 7.8 and 24.1(range 8.7–29.0) years, respectively.”
> “Mean and median ANO were 7.3 ± 4.1 and 6.8 (range 0–13) years.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="topic-3.1.5.8.2-5"></a>

##### Characteristics of the first three expanded access patients at entry

| Subject | Age and sex | NSS | Age at onset/diagnosis | Clinical pattern |
| --- | --- | --- | --- | --- |
| 01-001 | “14 F” | “31” | “6/12” | “Cortical cognitive>motor” |
| 01-002 | “15 M” | “2” | “13/13” | “Cortical cognitive>motor” |
| 01-003 | “17 F” | “10” | “10/16” | “Cerebellar motor>cognitive” |

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

> “All 3 subjects went on Miglustat at same age as diagnosis.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Company-presented survival by baseline disease burden, pooled clinical study and expanded access participants

> “Among the adrabetadex-treated participants with minimal disease burden at baseline, no deaths were recorded.”
> “Survival probability was markedly improved across the lower quartiles in both the adrabetadex-treated participants and the untreated cohort with adrabetadex-treated participants surviving longer in each quartile.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

| Median OS (95% CI), months | Minimal quartile | Mild quartile | Moderate quartile | Severe quartile |
| --- | --- | --- | --- | --- |
| Adrabetadex-treated participants | “NE (NE, NE)” | “136 (88, NE)” | “75 (60, NE)” | “55 (12, NE)” |
| Untreated cohort | “99 (39, 192)” | “111 (62, NE)” | “62 (28, NE)” | “29 (11, NE)” |

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.8.3-2"></a>

##### Company summary of the CNS 2026 survival and progression analyses

> “Among 76 individuals treated with adrabetadex for up to 11 years, those with the lowest baseline disease severity (as assessed by NPC Clinical Severity Scale, NPCCSS) demonstrated the longest survival observed (n=29; 100% survival at 5 years), supporting the importance of initiating adrabetadex treatment before advanced disease progression.”
> “Among 25 patients who received adrabetadex for at least five years, both prompt and delayed treatment initiation were associated with slower disease progression relative to published natural history data.”
> “Participants who initiated adrabetadex within one year of neurological symptom onset demonstrated less progression from baseline in NPCCSS scores compared with later treatment initiation, suggesting that earlier initiation of treatment with adrabetadex may result in greater long-term clinical benefit in I-NPC.”

Source: [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/)

<a id="topic-3.1.5.8.3-3"></a>

##### Time from onset to treatment in the prompt and delayed treatment groups

> “Participants with a delayed treatment initiation started receiving adrabetadex an average of 4.5 years following neurological onset; those with prompt treatment initiation started adrabetadex an average of 0.59 year after neurological onset.”

Source: [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.8.3-4"></a>

##### Sibling case report: early and delayed treatment initiation

> “Earlier initiation of adrabetadex for Sibling B (approximately 10 months from neurological symptom onset) led to maintenance of minimal disease activity after 10 years compared to an estimated age of death of 5.6 years without treatment.”

Source: [Julich et al. (2026)](https://medical.berentx.com/wp-content/uploads/2026/11/Julich_2026_CNS-Poster_Sibling-Case-Study_09Oct2026_Final-1.pdf)

> “Despite this delayed treatment initiation, she still experienced stabilization or improvement of her symptoms and she maintains moderate disease symptoms after approximately 10 years on adrabetadex.”

Source: [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/)

<a id="topic-3.1.5.8.3-5"></a>

##### Neurological outcomes in the first three expanded access patients over 2.5 to 3 years

> “No worsening in any domain except eye movements (vertical pursuit gain) was seen for any of the three patients, and in the other domains, improved scores on measures were seen over time for one or more patients.”
> “The NSS showed stable to slightly improved ratings.”
> “All three patients have shown substantial improvement in oral and pharyngeal phases of swallowing function as rated by the MBSImp (Table 4; Figure 6) and PAS.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.8.3-6"></a>

##### CSF 24(S)-hydroxycholesterol response after more than 4 years of treatment

> “Mean pre-drug administration CSF 24(S)OHC level was 0.27 ± 0.20 ng/ml.”
> “Mean CSF 24OHC level 48 hours after IT adrabetadex administration increased to 0.43 ± 0.22 ng/ml.”
> “This 1.6-fold average increase was significant (p=0.0289, paired t-test).”
> “24(S)OHC levels increased in 7 of the 10 individuals and the mean increase was 0.28 ± 0.34 ng/ml.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

<a id="topic-3.1.5.8.3-7"></a>

##### CSF neurofilament light chain in a cohort including expanded access participants

> “The population was derived from an observational/natural history study at the NIH Clinical Center in Bethesda, Maryland (NCT00001367), from a phase I/II intrathecal trial of adrabetadex (NCT01747135), from a phase II/III intrathecal trial of adrabetadex (NCT02534844) and from individuals receiving intrathecal adrabetadex through an expanded access program (IND 119856).”
> “By the last visit, 49 (42.2%) were on HPβCD.”
> “Over time, we did not observe a protective effect of HPβCD on NfL levels (OR=1.25, 95% CI 0.99–1.58) (Supplementary Figure 2A).”
> “In fact, when adjusting the longitudinal data for the protective effect of miglustat, HPβCD was associated with increased NfL levels (OR=1.35, 95% CI 1.09–1.67).”

Source: [Agrawal et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9992339/)

<a id="topic-3.1.5.8.3-8"></a>

##### CSF total tau in a cohort including expanded access participants

> “The data set consisted of 262 measurements from 101 individuals with NPC1.”
> “Intrathecal 2HPβCD therapy was associated with a reduction in CSF total Tau levels of 19% (FDR‐adjusted p = 0.008).”

Source: [Cawley et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11893204/)

<a id="topic-3.1.5.8.3-9"></a>

##### CSF neuron-specific enolase in expanded access participants

> “Paired CSF and serum samples were obtained from a subset of ten participants receiving IT HPβCD every 2–4 weeks under the EAP.”
> “Participants on IT HPβCD experienced an average decrease of 3.7 ± 2.9 ng/mL in CSF NSE levels per year, while those not on IT HPβCD showed an average annual increase of 2.6 ± 2.5 ng/mL.”
> “This difference was statistically significant (p = .0317), suggesting that IT HPβCD treatment may reduce CSF NSE levels over time (figure 4b).”

Source: [Padilla et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970998/)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.5.8.4-1"></a>

##### School and work functioning in the first three expanded access patients

> “001-02 has had stable school performance and graduated high school with a regular curriculum and some accommodations.”
> “001-03 has had stable performance in a community college and subsequent job training program and does well with office work.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Treatment-emergent adverse events in the expanded access program by combination therapy group

| Measure | Adrabetadex first, adrabetadex-only period (n=28) | Any combination exposure, combination period (n=33) | No combination after adrabetadex (n=53) | All EAP (n=86) |
| --- | --- | --- | --- | --- |
| With ≥1 TEAE (any grade), n (%) | “28 (100)” | “23 (69.7)” | “48 (90.6)” | “81 (94.2)” |
| Leading to death, n (%) | “0” | “1 (3.0)” | “5 (9.4)” | “6 (7.0)” |
| Serious AEs, n (%) | “13 (46.4)” | “8 (24.2)” | “24 (45.3)” | “41 (47.7)” |
| Grade ≥3, n (%) | “9 (32.1)” | “6 (18.2)” | “21 (39.6)” | “33 (38.4)” |
| TEAEs of interest, n (%) | “22 (78.6)” | “9 (27.3)” | “35 (66.0)” | “62 (72.1)” |
| Ataxia, n (%) | “10 (35.7)” | “5 (15.2)” | “23 (43.4)” | “37 (43.0)” |
| Fatigue, n (%) | “17 (60.7)” | “7 (21.2)” | “25 (47.2)” | “47 (54.7)” |
| Hearing impairment, n (%) | “10 (35.7)” | “2 (6.1)” | “15 (28.3)” | “26 (30.2)” |

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

> “TEAEs of interest and grade ≥3 TEAEs were similar across the groups and the overall EAP population, except for the group who were exposed to combination therapy at any point (lowest duration of adrabetadex exposure).”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.8.5-2"></a>

##### Hearing loss, post-dose ataxia and tiredness, and lumbar puncture events in the first three expanded access patients

> “Aside from hearing changes and post-dose tiredness/ataxia known to be associated with higher doses of HPβCD, adverse events have been predominantly unrelated to the lumbar punctures (LPs) or HPβCD (Table 3).”
> “Post-LP headaches and nausea in 001-01 and 001-02 for several initial doses essentially resolved after switching to the Whitacre needle for LPs.”
> “There was persistent ataxia and tiredness at 1200 mg (Table 3) and milder post-dose ataxia and tiredness at 900 mg, lasting 3–7 days.”
> “She continues on a dose of 300 mg (Table 3) due to an incremental hearing loss and tinnitus with each of three 400 mg doses.”
> “001-03 has an unusual sensitivity to hearing loss with HPβCD, as the extent of hearing loss seen in this patient at the 400 mg dose, is not known to have been observed in any other patient worldwide.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary: design limitations of the expanded access program analyses

- Control and setting: the original report of three patients names as limitations “the lack of a control group” and treatment through an expanded access protocol with likely more confounding changes from optimizing support and other treatments than in a clinical trial. Enrollment required that participants be ineligible for all currently enrolling clinical trials.
- Population counts: the prescribing information describes 85 participants (71 treatment-naïve and 14 previously treated) with a mean (SD) treatment duration of 44 (32) months.
- Dosing: doses started at 200 mg or 400 mg based on age, with titration up to 1200 mg in the initial protocol or 900 mg in the later revision, and dose adjustments were allowed.
- External comparison and analysis sets: the survival analysis by baseline disease burden compared 80 adrabetadex-treated participants with I-NPC (neurological onset <6 years) from clinical studies or the expanded access program with an untreated cohort of 44 from the NIH natural history study. Four treated participants without a baseline R4DNPCCSS score were excluded, leaving 76. Baseline was the last observation before the first dose for treated participants and the first available observation for the untreated cohort, and the authors state that “no matching procedure was performed between treated and untreated participants.”
- Prompt versus delayed treatment: the analysis included only participants with onset <6 years of age who had sustained treatment for at least 5 years, 9 with treatment initiation <1 year and 16 with initiation ≥1 year from onset, and miglustat use at baseline was 1 (11.1%) and 9 (56.3%), respectively. The company compared progression in these 25 participants with published natural history data.
- Combination therapy analysis: participants exposed to combination therapy had a shorter time since first treatment dose, as most started those therapies when they became commercially available at the end of 2024. Safety data were collected only while participants were in the study and receiving adrabetadex, and were not available for other NPC therapies received before enrollment.
- Concomitant miglustat: all three patients in the original report went on miglustat at the same age as diagnosis, and its authors state that an effect of miglustat or of the combination on progression cannot be ruled out. In the CSF neuron-specific enolase study, most participants receiving intrathecal HPβCD were also on miglustat, which the authors state makes it challenging to attribute the decrease to HPβCD alone.
- Sample size: the long-term 24(S)-hydroxycholesterol study included 10 individuals, and its authors state that its conclusions are limited by its small size; the CSF neuron-specific enolase study used a subset of ten expanded access participants.

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/); [Lembaz prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220996s000lbl.pdf); [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf); [Berry-Kravis et al. (2026f)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-EarlyTx_08Oct26_FINAL.pdf); [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf); [Beren Therapeutics CNS data press release (2026)](https://www.berentx.com/news/beren-therapeutics-presents-new-adrabetadex-data-showing-preservation-of-neurological-function-for-more-than-10-years-in-children-with-infantile-onset-npc/); [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/); [Padilla et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970998/)

<a id="topic-3.1.5.9-2"></a>

#### Authors' limitations of the original expanded access report

> “Limitations of this work include the lack of a control group and treatment through an expanded access protocol in which there are likely more confounding changes due to optimizing support and other treatments than would be seen in a clinical trial.”
> “it is impossible to rule out an effect on progression of the Miglustat or a combined effect of Miglustat and HPβCD, which target lipid storage in NPC via different mechanisms.”

Source: [Berry-Kravis et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5857219/)

<a id="topic-3.1.5.9-3"></a>

#### Unmatched comparison with the untreated cohort in the disease burden analysis

> “However, caution should be used when evaluating these two cohorts side-by-side, as no matching procedure was performed between treated and untreated participants.”

Source: [Berry-Kravis et al. (2026e)](https://medical.berentx.com/wp-content/uploads/2026/11/CNS2026-BaselineNPCCSS_08Oct26_FINAL.pdf)

<a id="topic-3.1.5.9-4"></a>

#### Shorter observation time in the combination therapy group

> “Those participants who were exposed to combination therapy at any point had a shorter time since first treatment dose in this analysis as most participants initiated these therapies when they became commercially available at the end of 2024.”

Source: [Berry-Kravis et al. (2026g)](https://medical.berentx.com/wp-content/uploads/2026/10/CNS2026-EAPComboTx_08Oct26_FINAL-.pdf)

<a id="topic-3.1.5.9-5"></a>

#### Small cohort size and concomitant miglustat in the biomarker studies

> “The conclusions of this study are limited by its small size; however, the data presented herein suggest that 24(S)OHC remains a robust proximal pharmacodynamic biomarker in individuals who have been treated for over four years with IT adrabetadex.”

Source: [Porter et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12638010/)

> “Given that most participants receiving IT HPβCD were also on miglustat, it is challenging to attribute the decrease in CSF NSE solely to IT HPβCD.”

Source: [Padilla et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11970998/)

## Related pages
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Terms and abbreviations](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/terms-and-abbreviations.md)
- [Adrabetadex (Lembaz): Infantile-onset Niemann-Pick disease type C](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/executive-summary.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Product information and disease description](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/product-information-and-disease-description.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Clinical evidence](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/clinical-evidence.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: Economic information and modeling report](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/economics.md)
- [Adrabetadex (Lembaz) in Infantile-onset Niemann-Pick disease type C: References](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references) · [Markdown](https://www.evicenter.com/drugs/adrabetadex--infantile-onset-niemann-pick-disease-type-c/references.md)
